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ABSTRACT
INTRODUCTION Healthcare associated infections (HCAIs) are falling following widespread and enforced introduction of guidelines,
particularly those that have addressed antibiotic resistant pathogens such as methicillin resistant Staphylococcus aureus or emer-
gent pathogens such as Clostridium difficile, but no such decline has been seen in the incidence of surgical site infection (SSI),
either in the UK, the EU or the US. SSI is one of the HCAIs, which are all avoidable complications of a surgical patient’s pathway
through both nosocomial and community care.
METHODS This report is based on a meeting held at The Royal College of Surgeons of England on 21 July 2016. Using PubMed,
members of the panel reviewed the current use of antiseptics and antimicrobial sutures in their specialties to prevent SSI.
FINDINGS The group agreed that wider use of antiseptics in surgical practice may help in reducing reliance on antibiotics in infec-
tion prevention and control, especially in the perioperative period of open elective colorectal, hepatobiliary and cardiac operative
procedures. The wider use of antiseptics includes preoperative showering, promotion of hand hygiene, (including the appropriate
use of surgical gloves), preoperative skin preparation (including management of hair removal), antimicrobial sutures and the man-
agement of dehisced surgical wounds after infection. The meeting placed emphasis on the level I evidence that supports the use of
antimicrobial sutures, particularly in surgical procedures after which the SSI rate is high (colorectal and hepatobiliary surgery) or
when a SSI can be life threatening even when the rate of SSI is low (cardiac surgery).
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Surgical site infection (SSI) presents a burden to healthcare
with significant morbidity and mortality. SSIs may double
hospital stay, with an annual increase in cost to the National
Health Service (NHS) of £65 million. After open elective col-
orectal surgery, the SSI rate has been estimated at 17.5%
(95% confidence interval [CI]: 13.3–22.9%), after sternotomy
for general cardiac surgery at 1.7% (95% CI: 0.9–3.3%) and
after coronary artery bypass grafting at 2.4% (95% CI: 1.6–
3.8%), with a time to peak presentation of 6–8 days, which
may be several days after the patient has returned home.1–3
Accurate data on SSI rates should include surveillance after
discharge,1,4 using extended follow-up review, telephonic
structured questionnaires and visitation by trained staff.5
Many surgeons are unaware of their individual SSI rates and
accurate surveillance may be seen to artificially raise SSI
rates.
The common pathogens that cause SSI are Staphylococcus
aureus, coagulase negative staphylococci (particularly after
implant surgery) and Enterobacteriaceae/anaerobes (partic-
ularly after colorectal surgery). This pattern is changing,
related to antibiotic use, and it is increasingly common to
see resistant bacterial strains.1 Factors that increase the SSI
rate include the category of wound (clean to dirty), presence
of implant or drain, length of surgery and preoperative stay,
carriage of S aureus, obesity, underlying chronic illnesses
and medication.6
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Definition of SSI
There are many definitions of SSI. The important clinical
features re peri-incisional erythema, serous or purulent
exudate and wound superficial dehiscence, which may be
accompanied by systemic signs, all of which lack specificity.
The most widely used definition is that of the US Centers for
Disease Control and Prevention but this is subjective and
provides only categorical data7 whereas the ASEPSIS (Addi-
tional treatment, Serous discharge, Erythema, Purulent exu-
date, Separation of deep tissues, Isolation of bacteria and
duration of Stay) score provides interval data useful in audit
and research, and allows an assessment of the severity of a
SSI.8
The SSI surveillance service of Public Health England and
Commissioning for Quality and Innovation of NHS England
have introduced a voluntary scheme covering 17 surgical
procedures. SSIs are registered on inpatient and readmis-
sion data only, and are used as performance indicators.1,2,9
This lack of accuracy has been criticised10,11 but only dili-
gent infection prevention surveillance and feedback of SSI
rates can achieve this accuracy – albeit at a cost.12
SSI care bundle concept
The care bundle concept has been shown to be effective for
prevention of SSI after colorectal surgery.13,14 Care bundles
comprise groups of evidence-based interventions each
ideally having level I effectiveness. However, for care bun-
dles to work, they have to rely on adequate compliance,
which can be low with only one in five patients receiving the
whole of an agreed bundle.10,15 Consequently, for the com-
parison of SSI rates, definitions, surveillance, differences in
case mix and effective reporting back to the surgical team
are important.
Ownership of a SSI bundle needs to involve the whole sur-
gical team and allied health professionals, preferably with a
surgical champion, to achieve the best results. Without the
‘buy in’, compliance is likely to fall and the bundle to fail.
SSIs are preventable (as all healthcare associated infections
[HCAIs] are) but there is little evidence that SSI rates are fall-
ing despite improved definition, surveillance and care bun-
dles. National schemes, with high quality surveillance and
rapid feedback, have not led to sustained reduction in SSIs
as they have done with infection prevention/control of other
HCAIs.
Antibiotic resistance: could antiseptics have a
wider role?
The rise of the incidence of HCAIs and antibiotic resistant
organisms, through selection and transmission, has been
blamed on the overuse and misuse of antibiotics. Neverthe-
less, according to the latest report by the US Food and Drug
Administration, approximately 80% of all antibiotics used in
the US are fed to farm animals.16 All these antibiotics ulti-
mately end up in the environment and food chain, adding to
the risk of resistant organisms. Before antibiotics became
widely available, there was a wealth of knowledge and use
of topical antimicrobials: the antiseptics.
There are many antiseptics available and used in surgical
practice (povidone-iodine and chlorhexidine) for preopera-
tive showering, skin and hand preparation, and open wound
management. Triclosan is a phenolic antiseptic that has
been used successfully to impregnate or coat synthetic
absorbable sutures such as polydioxanone, polyglactin and
poliglecaprone. This antiseptic has been used for skin prep-
aration and dental care as well as many inappropriate other
uses, with a broad spectrum of antibacterial and antifungal
properties and a low toxicity.17,18
The mechanisms of triclosan antimicrobial activity are
multifactorial and its action is bacteriostatic or bactericidal
depending on concentration. Some suspicions remain:
whether it can select resistant organisms, whether it can
influence antibiotic resistance and its transmission, whether
its overuse has environmental issues and whether it can
reduce SSIs when impregnated in or coated on sutures.
Triclosan inhibits bacterial fatty acid synthesis, repro-
duction and building of cell membranes by blocking enoyl-
acyl carrier protein reductase. There is innate resistance/
high tolerability to triclosan with some bacterial strains
through bacterial efflux pumps but these have little clinical
relevance, especially in regard to SSI. This theoretical risk
of resistance has been overstated, as have other health
risks relating to potentially harmful side products of triclo-
san degradation in the environment. Similarly, there are no
reported carcinogenic, mutagenic or teratogenic effects.17–
19 The comparatively very small amounts of triclosan used
to impregnate or coat absorbable polymer sutures pose no
risk to humans or the environment.20
SSI after colorectal, hepatobiliary and cardiac
surgery
As other nosocomial infections fall in incidence, SSI is
becoming the most common HCAI. After colorectal surgery,
superficial infections are much more common than deep or
organ/space SSIs (although the latter represent surgical fail-
ure such as anastomotic leak rather than a failure of bundle/
prophylaxis). It is in primary care that the majority of infec-
tions are seen, with poor data recording and a likelihood of
inappropriate care and healthcare costs (particularly for use
of antibiotics). Deep SSIs require prolonged hospital stays,
with the need for intensive care/high dependency unit
admission, further surgical interventions and extra treat-
ments. All these complications and overall survival are
worsened after rectal or emergency colorectal surgery, sur-
gery for inflammatory bowel disease, prolonged operations,
presence of a stoma and obesity.21–23 Compliance with care
bundles and even with surveillance programmes for SSI
incidence and prevention is not widespread in colorectal
surgical practice, nor is it supported by national
institutions.5,15,24
SSIs are also common after hepatobiliary surgery.25 In a
NHS hospital trust, a simple SSI infection prevention control
package of ten items has been found to more than halve SSIs
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after hepatobiliary surgery, with reduction of hospital stay.26
Savings from this bundle, which costs little to implement,
were equally substantial. However, in order to underwrite
its success, the introduction of the bundle needed a surgical
champion and team ownership as well as near perfect
compliance.
Cardiac surgery has a lower SSI rate but the consequen-
ces of deep sternal SSI relate to sternal closure instability,
mediastinitis and bone destruction with considerable mor-
bidity and mortality.27 Specific patient risk factors include
peripheral vascular disease, smoking, obesity and diabetes,
with operative risk factors being related to techniques of
sternal closure, duration of surgery, bilateral use of internal
thoracic arteries and need for postoperative ventilator sup-
port.28–30 Management may require extensive intervention,
including negative pressure therapy and flap reconstruction.
With the implementation of care bundles, the deep sternal
wound infection rate has fallen to <2% with a reoperation
rate of 0.6%.31,32
Are antimicrobial sutures effective?
All surgical wounds are contaminated by the time of clo-
sure and related to several risk factors.33 All sutures
(whether they are absorbable or unabsorbable, synthetic or
natural) represent a prosthetic implant; a 90cm length of
polyglactin presents a total surface area of 130cm2. The
presence of a suture increases the frequency of a SSI and
logarithmically lowers the number of organisms required
to produce a postoperative SSI from 106 or 105 to 102 col-
ony forming units.34,35
The importance of the role of biofilms has also been rec-
ognised; once a biofilm forms on the surface of a suture, its
contained organisms become recalcitrant to traditional anti-
microbials.36 Having a wide spectrum biocide (in this case,
the antiseptic triclosan) coated or impregnated in a suture
can provide high localised antimicrobial concentrations
around the suture, preventing it from becoming a nidus for
biofilm and infection. The advantage of using an antiseptic
as opposed to an antibiotic for this purpose is that triclosan
has the valuable benefits alluded to earlier.
The early experimental data on triclosan coated sutures
were supportive17,18 but some of the clinical trials were sci-
entifically flawed because of poor blinding, power calcula-
tions or randomisation. Many well designed studies have
since been published and deemed adequate in several sys-
tematic reviews and meta-analyses using PRISMA (Preferred
Reporting Items for Systematic reviews and Meta-Analyses)
guidelines.37–42 All these meta-analyses report a reduction of
approximately 30% in a population of several thousand
patients. The studies included general, gastrointestinal, col-
orectal, cardiac, vascular, breast and prosthetic surgical pro-
cedures. The study by Daoud et al specifically included
different classes of surgery (clean through to contaminated/
dirty) and found the same advantage could be attributed to
antimicrobial sutures with no publication bias and a robust
sensitivity analysis.39 It concluded that the 33% (95% CI: 16–
46%) advantage proffered by antimicrobial sutures was
level I evidence.
A more recent scientifically acceptable RCT was more
cautious in its findings in colorectal surgery.43 The study
was probably too underpowered to show a significant differ-
ence in deep SSIs (although they were reduced), and it was
limited by not having the subcutaneous and subcuticular
layers closed with an antimicrobial suture. It is unlikely that
closure using an antimicrobial suture, only in the deeply
placed, musculofascial layer, could prevent a superficial SSI.
Conclusions
A pivotal component of the discussion must be: ‘Why should
a surgeon choose to use an antimicrobial suture in his or
her clinical practice?’ When triclosan coated, braided poly-
glactin sutures were first introduced in 1992, there was sig-
nificant scepticism over its perceived benefit. This was, in
part, driven by a lack of published clinical studies document-
ing efficacy, coupled with a poor understanding of how an
innovative suture technology could assist in preventing SSIs.
Published in vitro laboratory and animal studies document-
ing benefit were viewed as insufficient rationale for adopt-
ing this technology in routine clinical practices.
Three factors have now played a significant role in tipping
the balance for the use of an antimicrobial suture technology
in surgical practice. The first is the eventual completion of
well designed surgical studies published in peer reviewed
surgical journals, which culminated in publication of rigor-
ous meta-analyses,39–41 documenting 1a clinical benefit.
Second, there is recognition that the antimicrobial suture
should not be viewed as a ‘silver bullet’ but rather as part of
a designed-for-purpose, evidence-based, interventional risk
reduction strategy. Finally, recognition of the benefits associ-
ated with use of a triclosan coated suture has culminated in
universal endorsement of this technology by governmental
and professional associations and organisations. The World
Health Organization,44 the American College of Surgeons/
Surgical Infection Society45 and the Healthcare Infection
Control Practices Advisory Committee of the Centers for Dis-
ease Control (to be published in 2017) have all endorsed the
use of triclosan coated/impregnated suture technology as an
effective risk reduction strategy for SSIs.
In evaluating the decision whether to adopt an antimicro-
bial suture in a perioperative care bundle, four levels of evi-
dence should be considered: safety, microbicidal activity,
clinical effectiveness and cost effectiveness. While clinical
effectiveness has been addressed adequately in this review,
patient safety associated with use of any invasive innovative
technology should be of paramount concern to all surgeons.
In the 14 years since triclosan sutures have been commer-
cially available, there have been no reports to the Food and
Drug Administration Manufacturer and User Facility Device
Experience website indicating any significant adverse
events such as wound dehiscence, delayed healing, emer-
gence of resistant organisms, toxicity or allergic reactions.46
Furthermore, these sutures exhibit a robust antimicrobial
activity, appropriate for common surgical wound pathogens.
Finally, several economic analyses have documented a fiscal
benefit associated with the use of this technology in both
paediatric and adult surgical procedures.47–49
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Surgical practitioners should now approach their disci-
pline from an evidence-based perspective and include the
use of effective surgical care bundles in their clinical prac-
tice. The option of using a triclosan coated/impregnated
antimicrobial suture in a surgical care bundle should always
represent individual preference. However, that decision is
now easily made in light of the wealth of evidence support-
ing the benefit of an antimicrobial closure technology in the
presence of co-morbid patient risk factors. For maximum
benefit, triclosan coated or impregnated antimicrobial
sutures should be used to close all layers of the surgical
wound since wound contamination is often linear. Finally,
an ancillary benefit of any evidence-based approach for
reducing the risk of SSI could lead to a diminished need for
perioperative antibiotic therapy, which fits well in our global
mandate of effective antibiotic stewardship.
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